Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Go back to Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
(NASDAQ: ADAG) Delayed: 3.30 +0.03 (0.92%)
Previous Close $3.27    52 Week High
Open $3.54    52 Week Low
Day High $3.55    P/E N/A 
Day Low $3.20    EPS
Volume 87,359